Literature DB >> 11607770

Effect of extended immunosuppressive drug treatment on B cell vs T cell reconstitution in pediatric bone marrow transplant recipients.

S D'Costa1, K S Slobod, E Benaim, L Bowman, J Cunningham, M Holladay, N Howlett, D K Srivastava, J L Hurwitz.   

Abstract

Allogeneic bone marrow transplantation (BMT) is an effective therapy for a variety of malignancies and blood disorders, but rarely serves as a frontline treatment because of numerous, potential complications. Important and frequent complications relate to the profound immunosuppression that inevitably occurs during the first several months following treatment. To better elucidate and subsequently improve immune reconstitution, we examined T and B cell subsets among 43 pediatric BMT recipients in a retrospective study. We found that the relative numbers of T cells and B cells (T:B ratios) were discordant and highly variable among patients at day approximately 100 after BMT. Further investigation of BMT parameters identified a strong correlation between T:B ratios and immunosuppressive drug treatments, providing an explanation for variable lymphocyte reconstitution profiles. Results suggest that: (1) immunosuppressive therapy inhibits B cell expansion more strongly than T cell expansion following BMT; (2) WBC and absolute lymphocyte counts fail to reveal profound B cell immunodeficiencies in some BMT patients; and (3) routine analyses of T:B ratios serve to identify patients warranting close follow-up and extended supportive immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11607770     DOI: 10.1038/sj.bmt.1703185

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  4 in total

Review 1.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report.

Authors:  Juan Gea-Banacloche; Krishna V Komanduri; Paul Carpenter; Sophie Paczesny; Stefanie Sarantopoulos; Jo-Anne Young; Nahed El Kassar; Robert Q Le; Kirk R Schultz; Linda M Griffith; Bipin N Savani; John R Wingard
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-14       Impact factor: 5.742

Review 2.  Mass Cytometry for the Assessment of Immune Reconstitution After Hematopoietic Stem Cell Transplantation.

Authors:  Lauren Stern; Helen McGuire; Selmir Avdic; Simone Rizzetto; Barbara Fazekas de St Groth; Fabio Luciani; Barry Slobedman; Emily Blyth
Journal:  Front Immunol       Date:  2018-07-26       Impact factor: 7.561

Review 3.  Regulatory B cells: TIM-1, transplant tolerance, and rejection.

Authors:  Aravind Cherukuri; Kanishka Mohib; David M Rothstein
Journal:  Immunol Rev       Date:  2021-01-22       Impact factor: 12.988

4.  Prevalence of hypogammaglobulinemia and its management with subcutaneous immunoglobulin supplementation in patients after allogeneic hematopoietic stem cell transplantation-a single-center analysis.

Authors:  Ewa Karakulska-Prystupiuk; Jadwiga Dwilewicz-Trojaczek; Joanna Drozd-Sokołowska; Ewelina Kmin; Marcin Chlebus; Karolina Szczypińska; Piotr Boguradzki; Agnieszka Tomaszewska; Krzysztof Mądry; Jarosław Biliński; Grzegorz Władysław Basak; Wiesław Wiktor Jędrzejczak
Journal:  Ann Hematol       Date:  2021-09-03       Impact factor: 4.030

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.